Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group. Issue 12 (30th August 2013)

• Record Type: Journal Article
• Authors: Johnston, Donna L.; Alonzo, Todd A.; Gerbing, Robert B.; Hirsch, Betsy; Heerema, Nyla A.; Ravindranath, Yaddanapudi; Woods, William G.; Lange, Beverly J.; Gamis, Alan S.; Raimondi, Susana C.
• Is Part Of: Pediatric blood & cancer. Volume 60:Issue 12(2013:Dec.)
• Page Start: 2073
• Page End: 2078
• Publication Date: 2013-08-30
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24573
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24573-sec-0001" sec-type="section"> <title>Background</title> <p>Abnormalities of chromosome 5q (−5/5q−) are associated with poor prognosis in adults with acute myeloid leukemia (AML). However, there are no large studies on outcomes of children with −5/5q− AML. To determine the disease correlates of this group, we retrospectively analyzed cytogenetic data from five studies of childhood AML.</p> </sec> <sec id="pbc24573-sec-0002" sec-type="section"> <title>Procedure</title> <p>Data from patients whose cytogenetic clones included −5/5q−, with the exception of those with acute promyelocytic leukemia or Down syndrome, were included.</p> </sec> <sec id="pbc24573-sec-0003" sec-type="section"> <title>Results</title> <p>Of the 2, 240 patients with cytogenetic data available, 26 (1.2%) had −5 or 5q−. A significant number of these patients were age 11–21 (61.5%, <italic>P</italic> = 0.031) and had M0 morphology compared with patients without −5/5q− (24.0% vs. 2.8%, <italic>P</italic> < 0.001). Twenty‐two of the 26 patients had a complete remission (CR) response to induction chemotherapy. The 5‐year overall survival (OS) from the time of diagnosis for the −5/5q− patients was significantly lower than for patients without −5/5q− (27 ± 17% vs. 50 ± 2%, <italic>P</italic> = 0.027). Similarly, from induction CR, patients with −5/5q− had significantly worse disease free survival, OS and relapse risk than those without this abnormality (27 ± 19% vs. 46 ± 2%, <italic>P</italic> = 0.035, 32 ± 20% vs. 57 ± 2%, <italic>P</italic> = 0.025, 68 ± 21% vs. 45 ± 2%, <italic>P</italic> = 0.01, respectively).</p> </sec> <sec id="pbc24573-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Pediatric patients with AML and −5/5q− had a very poor outcome. These findings support the need for new or novel therapies for these patients. Pediatr Blood Cancer 2013;60:2073–2078. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>